 |
|
Annotation rule MF_01964 |
General rule information
[?]
Accession |
MF_01964 |
Dates |
5-JAN-2012 (Created) 19-NOV-2019 (Last updated, Version 10) |
case <OC:Bacteria> or <OC:Archaea>
end case
Propagated annotation
[?]
Identifier, protein and gene names
[?]
Protein name |
RecName:
|
Full=Inosine-5'-monophosphate dehydrogenase;
|
|
Short=IMP dehydrogenase;
|
|
Short=IMPD;
|
|
Short=IMPDH;
|
|
EC 1.1.1.205;
|
|
Function |
Catalyzes the conversion of inosine 5'-phosphate (IMP) to xanthosine 5'-phosphate (XMP), the first committed and rate-limiting step in the de novo synthesis of guanine nucleotides, and therefore plays an important role in the regulation of cell growth. |
Catalytic activity |
RHEA:11708: H2O + IMP + NAD(+) = H(+) + NADH + XMP
EC 1.1.1.205
|
Cofactor |
K(+) |
Activity regulation |
Mycophenolic acid (MPA) is a non-competitive inhibitor that prevents formation of the closed enzyme conformation by binding to the same site as the amobile flap. In contrast, mizoribine monophosphate (MZP) is a competitive inhibitor that induces the closed conformation. MPA is a potent inhibitor of mammalian IMPDHs but a poor inhibitor of the bacterial enzymes. MZP is a more potent inhibitor of bacterial IMPDH. |
Pathway |
Purine metabolism; XMP biosynthesis via de novo pathway; XMP from IMP: step 1/1. |
Subunit |
Homotetramer. |
Similarity |
Belongs to the IMPDH/GMPR family. |
GO:0003938; Molecular function: IMP dehydrogenase activity.
GO:0046872; Molecular function: metal ion binding.
GO:0000166; Molecular function: nucleotide binding.
GO:0006177; Biological process: GMP biosynthetic process.
From: IMDH_TRIFO (P50097) |
Key
|
|
From
|
|
To
|
|
Description
|
|
Tag
|
|
Condition
|
|
FTGroup
|
NP_BIND (Optional)
|
|
261
|
|
263
|
|
NAD
|
|
|
|
D-S-S
|
|
|
case not <FT:1=D-S-S>
BINDING (Optional)
|
|
261
|
|
261
|
|
NAD
|
|
|
|
D
|
|
|
end case
NP_BIND
|
|
312
|
|
314
|
|
NAD
|
|
|
|
G-x-G
|
|
|
REGION
|
|
358
|
|
360
|
|
IMP binding
|
|
|
|
D-G-G
|
|
|
REGION
|
|
381
|
|
382
|
|
IMP binding
|
|
|
|
G-x
|
|
|
REGION
|
|
405
|
|
409
|
|
IMP binding
|
|
|
|
[YI]-x-x-x-[GA]
|
|
|
ACT_SITE
|
|
319
|
|
319
|
|
Thioimidate intermediate
|
|
|
|
C
|
|
|
ACT_SITE
|
|
418
|
|
418
|
|
Proton acceptor
|
|
|
|
R
|
|
|
METAL
|
|
314
|
|
314
|
|
Potassium; via carbonyl oxygen
|
|
|
|
G
|
|
|
METAL
|
|
316
|
|
316
|
|
Potassium; via carbonyl oxygen
|
|
|
|
G
|
|
|
METAL
|
|
319
|
|
319
|
|
Potassium; via carbonyl oxygen
|
|
|
|
C
|
|
|
METAL (Optional)
|
|
485
|
|
485
|
|
Potassium; via carbonyl oxygen; shared with tetrameric partner
|
|
|
|
E
|
|
|
METAL (Optional)
|
|
486
|
|
486
|
|
Potassium; via carbonyl oxygen; shared with tetrameric partner
|
|
|
|
[GS]
|
|
|
METAL (Optional)
|
|
487
|
|
487
|
|
Potassium; via carbonyl oxygen; shared with tetrameric partner
|
|
|
|
[GH]
|
|
|
BINDING
|
|
317
|
|
317
|
|
IMP
|
|
|
|
S
|
|
|
BINDING
|
|
431
|
|
431
|
|
IMP
|
|
|
|
[EQ]
|
|
|
Additional information
[?]
Size range |
400-554 amino acids |
Related rules |
None |
Fusion |
None |